Search...
Sun Pharma's unit Taro to acquire 100% stake in Antibe Therapeutics
I'm PortAI, I can summarize articles.
Sun Pharmaceutical's subsidiary, Taro Pharmaceuticals, is set to acquire a 100% stake in Antibe Therapeutics, a clinical-stage biotech firm in Ontario, Canada. The deal, aimed at enhancing Sun Pharma's portfolio in pain and inflammation management, is expected to close by March 7, 2025, pending court approval. Antibe, founded in 2009, has been under receivership and has not generated revenue for three years. The acquisition will be in cash, with details disclosed post-transaction. Following the announcement, Sun Pharma's stock rose by 0.38% to Rs 1,763.50.
Source: Business Standard The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments